GO
Loading...

Pharmaceuticals

More

  • Game Plan for the Week of June 25 Monday, 25 Jun 2007 | 9:32 AM ET

    Did the Bear Stearns hedge-fund blowup scare you out of the market? Here are some picks to get you back in.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Drug maker Schering-Plough said Monday it received expanded European approval for a combination therapy of Pegintron and Rebetol to treat hepatitis C patients who are also infected with HIV.

  • On the Line: Acadia Pharma CEO Uli Hacksell Friday, 22 Jun 2007 | 11:24 AM ET

    With the pipeline this company has, Cramer thinks this $14 stock could hit $20 by this time next year.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Michael Moore's "Sicko" Summer Thursday, 21 Jun 2007 | 12:03 PM ET
    Michael Moore

    The tables have turned. Over the past couple of years I've been to a number of pharmaceutical industry related and drug company events--where the security and paranoia have been noticeably increased over what I referred to as "The Michael Moore Effect". Ever since it became known that the documentary filmmaker was setting his sites on healthcare the companies I cover have been on heightened alert. But, at least for now, I think they can let their guard down.

  • Pfizer said after markets closed Wednesday that U.S. health regulators will approve its novel AIDS drug called maraviroc once certain conditions have been met, although the world's biggest drugmaker did not elaborate on what was necessary to obtain an outright approval.

  • CNBC's Schacknow: Huckman's Crystal Ball Tuesday, 19 Jun 2007 | 3:04 PM ET

    We can’t all be experts at everything, which is why we have people who are experts at something. Having said that, I’ll let you in on one of my little secrets -- how to tell when a pharmaceutical story has significance. ... Also: a seemingly innocuous headline -- about Expedia -- has plenty of hidden meaning.

  • A More "Crystal" Bristol-Myers After Ruling Tuesday, 19 Jun 2007 | 2:23 PM ET

    Bristol-Myers Squibb's future looks a lot clearer. A federal judge this morning ruled the patent on the bloodthinner Plavix which Bristol shares with Sanofi-Aventis is valid. And Judge Sidney Stein added the companies are entitled to injunctive relief and damages. Money. It'll come from the scrappy, pesky, Canadian, privately-held generic drug company "Apotex". Last summer Apotex took advantage of a legal loophole in a sweet side deal it negotiated with Bristol and launched generic Plavix.

  • A U.S. judge on Tuesday ruled that the patent on the multibillion-dollar blood clot-preventing drug Plavix is valid, handing a major victory to Bristol-Myers Squibb and Sanofi-Aventis.

  • Shares of Bristol, Sanofi Rise On Plavix Ruling Tuesday, 19 Jun 2007 | 11:18 AM ET

    A U.S. judge Tuesday ruled that the patent on the multibillion-dollar blood clot preventer Plavix is valid, handing a major victory to Bristol-Myers Squibb and Sanofi-Aventis. Shares of both companies rose on the news.

  • Bristol Breast Cancer Drug Granted Priority FDA Review Tuesday, 19 Jun 2007 | 8:22 AM ET

    U.S. health regulators have granted priority review for Bristol-Myers Squibb experimental breast cancer drug ixabepilone, and an approval decision on the medicine could come by late October, the company said on Tuesday.

  • Earnings news and clinical trial data were some of the catalysts behind the most actively traded stocks on Monday.

  • GlaxoSmithKline plans to launch five new cancer drugs by 2010, tapping into a $40 billion-a-year market that is growing by 20 percent annually, its research head said on Monday.

  • A Biotech Buy for the Bold Friday, 15 Jun 2007 | 8:00 PM ET

    If CV Therapeutics doubles, take profits. If it gets clobbered, at least the company’s best drug can treat your angina.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Gilead Sciences shares rose in aftermarket trading on Friday after the U.S. Food and Drug Administration approved the drugmaker's treatment for high blood pressure in the lungs.

  • Double D: Diets and Dendreon Thursday, 14 Jun 2007 | 2:54 PM ET
    Alli Diet Pills

    Today's the day! Wal-Mart starts selling the first FDA-approved, over-the-counter weightloss pill today. GlaxoSmithKline says Alli should be on drugstore and discount store shelves everywhere by tomorrow. Alli is the diet pill that can have embarrassing gastrointestinal side effects. Coincidentally, the launch occurs the day after an FDA Advisory Committee shut out Sanofi-Aventis' weightloss pill Zimulti.

  • Analyst actions and corporate announcements were some of the catalysts behind the most actively traded stocks on Thursday.

  • Investors wiped some 6 billion euros ($7.97 billion) off the market value of French pharmaceutical company Sanofi-Aventis Thursday after U.S. federal health advisers rejected its Accomplia weight-loss drug.

  • Analyst actions and clinical trial data were some of the catalysts behind the most actively traded stocks on Wednesday.

  • Novartis Gets EU OK for New Flu Vaccine Wednesday, 13 Jun 2007 | 4:25 AM ET

    Swiss drugmaker Novartis said Wednesday it has received European Union approval for flu vaccine Optaflu.

  • Buying Big Pharma - If You Must Tuesday, 12 Jun 2007 | 7:03 PM ET

    It’s slim pickings in the sector, but there are a couple of stocks that are actually worth buying, Cramer says.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

Most Popular Video

Wednesday, 16 Apr 2014 | 9:37 AM ET

CNBC's Bob Pisani looks at what's likely to move in early morning trading, including the public debut of Moelis & Company, and a look at bank earnings and market leaders.

Wednesday, 16 Apr 2014 | 7:50 AM ET

John Calipari, University of Kentucky basketball coach, discusses building "servant leadership" in his team, and the big business of college basketball.

Wednesday, 16 Apr 2014 | 9:04 AM ET

The "Squawk on the Street" news team break down Bank of America's Q1 earnings loss thanks largely to legal expenses related to the financial crisis.